Compare Saptak Chem & with Similar Stocks
Dashboard
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of % and Operating profit at 0% over the last 5 years
- The company has a negative book value of Rs 2.34 crore
Negative results in Dec 25
Risky - Negative EBITDA
Stock DNA
Trading & Distributors
INR 15 Cr (Micro Cap)
716.00
23
0.00%
-1.05
-0.43%
-6.24
Total Returns (Price + Dividend) 
Saptak Chem & for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News
When is the next results date for Saptak Chem & Business Ltd?
The next results date for Saptak Chem & Business Ltd is scheduled for 14 May 2026....
Read full news article
Saptak Chem & Business Ltd Downgraded to Strong Sell Amid Mixed Technicals and Weak Financials
Saptak Chem & Business Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 23 April 2026, reflecting a complex interplay of deteriorating financial fundamentals, challenging valuation metrics, and mixed technical signals. Despite impressive stock returns over the past year, the company’s underlying financial health and long-term growth prospects have raised significant concerns among analysts.
Read full news article
Saptak Chem & Business Ltd Upgraded to Sell Amid Mixed Financial and Technical Signals
Saptak Chem & Business Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 17 April 2026, reflecting nuanced changes across quality, valuation, financial trends, and technical parameters. Despite persistent fundamental weaknesses, the stock’s recent market performance and valuation dynamics have prompted a reassessment by analysts, signalling cautious optimism amid ongoing risks.
Read full news article Announcements 
Board Meeting Intimation for Audited Financial Result For The Quarter And Financial Year Ended On 31St March 2026 Along With The Auditors Report And Certificate For Unmodified Opinion
08-May-2026 | Source : BSESaptak Chem And Business Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 inter alia to consider and approve Audited financial result for the quarter and financial year ended on 31st March 2026 along with the Auditors Report and Certificate for unmodified opinion
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30-Apr-2026 | Source : BSEFormat of Initial Disclosure to be made by an entity identified as a Large Corporate.
| Sr. No. | Particulars | Details |
| 1 | Name of Company | Saptak Chem And Business Ltd |
| 2 | CIN NO. | L24299GJ1980PLC101976 |
| 3 | Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) | 0.00 |
| 4 | Highest Credit Rating during the previous FY | NA |
| 4a | Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4) | Not Applicable |
| 5 | Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework | BSE |
Designation: Company Secretary and Compliance Secretary
EmailId: munakchem1980@gmail.com
Designation: Chief Financial Officer
EmailId: munakchem1980@gmail.com
Date: 30/04/2026
Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011
10-Apr-2026 | Source : BSEThe Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Ankush Agarwal HUF
Corporate Actions 
14 May 2026
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Non Institution
None
Held by 0 Schemes
Held by 0 FIIs
Alpha Antibiotics Limited (12.58%)
Saptak Chem (24.13%)
46.64%
Quarterly Results Snapshot (Standalone) - Dec'25 - YoY
YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024
YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024
Growth in half year ended Sep 2025 is -700.00% vs 0.00% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 0.00% vs 0.00% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -1,800.00% vs 0.00% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'25
YoY Growth in year ended Mar 2025 is 0.00% vs -100.00% in Mar 2024
YoY Growth in year ended Mar 2025 is -200.00% vs -400.00% in Mar 2024






